Docking studies on PARP-1 inhibitors: insights into the role of a binding pocket water molecule

被引:56
作者
Bellocchi, D [1 ]
Macchiarulo, A [1 ]
Costantino, G [1 ]
Pellicciari, R [1 ]
机构
[1] Univ Perugia, Dipartimento Chim & Tecnol Farmaco, I-06123 Perugia, Italy
关键词
PARP; docking; structural water; desolvation energy;
D O I
10.1016/j.bmc.2004.11.024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The binding mode of a series of competitive PARP-1 inhibitors was investigated employing a molecular docking approach by using Autodock 3.0. A particular attention was given to the role played by a water molecule present in some but not all the so far available crystal structures of the catalytic domain of PARP-1. Good correlation between calculated binding energies and experimental inhibitory activities was obtained either by including (r(2) = 0.87) or not (r(2) = 0.84) the structural water molecule. Closer inspection of our results suggested that this water molecule should be considered part of the hydration shell of polar inhibitors and not as a structural water. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1151 / 1157
页数:7
相关论文
共 28 条
[1]  
*ACC INC, CER J 0 MOL MOD SOFT
[2]  
BANASIK M, 1992, J BIOL CHEM, V267, P1569
[3]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[4]   Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064 [J].
Bowman, KJ ;
White, A ;
Golding, BT ;
Griffin, RJ ;
Curtin, NJ .
BRITISH JOURNAL OF CANCER, 1998, 78 (10) :1269-1277
[5]   Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: Pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia [J].
Chiarugi, A ;
Meli, E ;
Calvani, M ;
Picca, R ;
Baronti, R ;
Camaioni, E ;
Costantino, G ;
Marinozzi, M ;
Pellegrini-Giampietro, DE ;
Pellicciari, R ;
Moroni, F .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :943-949
[6]   Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis [J].
Costantino, G ;
Macchiarulo, A ;
Camaioni, E ;
Pellicciari, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) :3786-3794
[7]   Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse [J].
de Murcia, JMN ;
Ricoul, M ;
Tartier, L ;
Niedergang, C ;
Huber, A ;
Dantzer, F ;
Schreiber, V ;
Amé, JC ;
Dierich, A ;
LeMeur, M ;
Sabatier, L ;
Chambon, P ;
de Murcia, G .
EMBO JOURNAL, 2003, 22 (09) :2255-2263
[8]  
Delaney CA, 2000, CLIN CANCER RES, V6, P2860
[9]  
DEMURCIA G, 2003, PARP 2003 LISB PORT
[10]   Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia [J].
Eliasson, MJL ;
Sampei, K ;
Mandir, AS ;
Hurn, PD ;
Traystman, RJ ;
Bao, J ;
Pieper, A ;
Wang, ZQ ;
Dawson, TM ;
Snyder, SH ;
Dawson, VL .
NATURE MEDICINE, 1997, 3 (10) :1089-1095